Maeda Koji, Ohki Takao, Kanaoka Yuji, Baba Takeshi, Kaneko Kenjirou, Shukuzawa Kota
Division of Vascular Surgery, Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.
Division of Vascular Surgery, Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.
Ann Vasc Surg. 2017 May;41:96-104. doi: 10.1016/j.avsg.2016.08.045. Epub 2017 Feb 24.
To evaluate the optimal treatment for juxtarenal abdominal aortic aneurysm (JAAA), we compared the outcomes of open surgical repair (OSR) with endovascular aortic repair (EVAR) using a variety of fenestrated and snorkel EVARs.
We evaluated overall survival, aneurysm-related death, reintervention, and renal impairment in 152 JAAAs retrospectively, excluding cases of aortic dissection and rupture. Cox models were used to assess survival and assessed postoperative dialysis rates following surgery.
OSR and EVAR were performed in 81 and 71 patients, respectively. The mean age was significantly higher in the EVAR group (overall, 74.5 years; OSR, 71 years; and EVAR; 77 years). High preoperative serum creatinine levels, cerebrovascular disease, and chronic obstructive pulmonary disease were more prevalent in the EVAR group. Mean operative time, hospital stay, and perioperative blood loss were significantly greater in the OSR group (P < 0.001 for all). The overall 30-day mortality was 1.9% with no statistical difference between 2 groups. The reintervention rate was significantly higher in the EVAR group (P = 0.01). Overall survival rates at 1, 3, 5, and 7 years were 97.4%, 91.6%, 86.3%, and 82.9%, respectively, with no significant difference between groups. Mortality in EVAR was associated with over 3.0 mg/dL of postoperative creatinine, and postoperative dialysis following OSR was associated with operative time and volume of bleeding.
Acceptable outcomes were observed with OSR and EVAR. However, reintervention was more frequently required following EVAR. OSR appears to be the most appropriate first-line treatment for JAAA in good-risk patients; however, EVAR may represent an alternative option in high-risk patients.
为评估近肾腹主动脉瘤(JAAA)的最佳治疗方法,我们比较了开放手术修复(OSR)与使用各种开窗和带延长分支的腔内主动脉修复(EVAR)的疗效。
我们回顾性评估了152例JAAA患者的总生存率、动脉瘤相关死亡、再次干预和肾功能损害情况,排除主动脉夹层和破裂病例。采用Cox模型评估生存率,并评估术后透析率。
分别对81例和71例患者进行了OSR和EVAR治疗。EVAR组的平均年龄显著更高(总体为74.5岁;OSR组为71岁;EVAR组为77岁)。术前血清肌酐水平高、脑血管疾病和慢性阻塞性肺疾病在EVAR组中更为普遍。OSR组的平均手术时间、住院时间和围手术期失血量显著更多(均P<0.001)。总体30天死亡率为1.9%,两组间无统计学差异。EVAR组的再次干预率显著更高(P=0.01)。1年、3年、5年和7年的总生存率分别为97.4%、91.6%、86.3%和82.9%,两组间无显著差异。EVAR术后死亡率与术后肌酐超过3.0mg/dL相关,OSR术后透析与手术时间和出血量相关。
OSR和EVAR均观察到了可接受的疗效。然而,EVAR后更频繁地需要再次干预。对于低风险患者,OSR似乎是JAAA最合适的一线治疗方法;然而,EVAR可能是高风险患者的替代选择。